Company Pacific Edge Limited

Equities

PEB

NZPEBE0002S1

Biotechnology & Medical Research

End-of-day quote New Zealand S.E. 06:00:00 2024-06-13 pm EDT 5-day change 1st Jan Change
0.099 NZD +1.02% Intraday chart for Pacific Edge Limited -1.98% -15.38%

Business Summary

Pacific Edge Limited is a global cancer diagnostics company. The Company is engaged in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The Company operates through two segments: Commercial and Research. The Commercial segment is engaged in the sales, marketing, laboratory, and support operations to run the commercial businesses worldwide. The Research segment is engaged in the research and development of diagnostic and prognostic products for human cancer. The Company provides its suite of Cxbladder tests globally through its wholly owned laboratories in New Zealand and the United States. Its Cxbladder tests assist clinicians to safely de-intensify hematuria evaluation from low incidence populations; resolve diagnostic dilemmas and monitor patients for the recurrence of urothelial carcinoma. It operates in New Zealand, Australia, Singapore, and the United States.

Sales per Business

NZD in Million2023Weight2024Weight Delta
Commercial
99.8 %
20 100.0 % 24 99.8 % +21.69%
Eliminations
0.2 %
- - 0 0.2 % -

Sales per region

NZD in Million2023Weight2024Weight Delta
United States
94.1 %
19 95.6 % 23 94.1 % +20.01%
Rest of World
5.9 %
1 4.4 % 1 5.9 % +62.24%

Managers

Managers TitleAgeSince
Chief Executive Officer - 22-01-16
Director of Finance/CFO - 19-12-15
Chief Tech/Sci/R&D Officer - 03-12-31
Chief Operating Officer - 22-10-02
Chief Tech/Sci/R&D Officer - -
Corporate Officer/Principal - 21-05-31

Members of the board

Members of the board TitleAgeSince
Chairman - 16-06-30
Director/Board Member 74 13-07-03
Director/Board Member - 22-03-20
Director/Board Member - 08-03-31
Director/Board Member - 21-03-14
Director/Board Member - 18-12-05
Director/Board Member - 21-05-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 811,271,000 729,383,060 ( 89.91 %) 0 89.91 %
Stock B 0 152,500 0 0

Shareholders

NameEquities%Valuation
Harbour Asset Management Ltd.
14.34 %
116,356,180 14.34 % 7 M $
ANZ New Zealand Investments Ltd.
9.700 %
78,690,251 9.700 % 5 M $
BT Funds Management (NZ) Ltd.
6.510 %
52,810,384 6.510 % 3 M $
Salt Funds Management Ltd.
5.931 %
48,114,089 5.931 % 3 M $
22,121,378 2.727 % 1 M $
K One W One Ltd.
2.600 %
21,091,520 2.600 % 1 M $
5,537,037 0.6825 % 347 006 $
3,425,000 0.4222 % 214 645 $
3,140,000 0.3870 % 196 784 $
3,000,000 0.3698 % 188 010 $

Company contact information

Pacific Edge Ltd.

Centre for Innovation 87 St. David Street

9016, Dunedin

+

http://www.pacificedgedx.com
address Pacific Edge Limited(PEB)

Sales per Business

Sales per region

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.099 NZD
Average target price
0.13 NZD
Spread / Average Target
+31.31%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. PEB Stock
  4. Company Pacific Edge Limited